Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…Abstract Number: 2577 • ACR Convergence 2025
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Background/Purpose: People with rheumatic diseases are at risk for acute and post-acute COVID-19 outcomes in part due to immunosuppressive medications. Those on B-cell depleting therapies…Abstract Number: 1444 • ACR Convergence 2025
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…Abstract Number: 0202 • ACR Convergence 2025
Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of infections due to both immune system dysfunction and the use of immunosuppressive…Abstract Number: 2373 • ACR Convergence 2025
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease affecting joints, entheses, skin, nails, and spine. While treatment options have expanded, TNF inhibitors (TNFis) remain the…Abstract Number: 1440 • ACR Convergence 2025
Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
Background/Purpose: We aimed to compare the demographic and clinical characteristics of the patients with axial spondyloarthritis (aSpA) receiving standard-dose versus tapered-dose biologic disease-modifying antirheumatic drugs…Abstract Number: 0108 • ACR Convergence 2025
In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease for which TNFα inhibitors are the standard first-line biologic therapy. Nonetheless, a significant proportion of patients…Abstract Number: 2370 • ACR Convergence 2025
Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated disease which involves joints, skin, and nails, leading to deformities, decreased function, lower quality of life, and…Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…Abstract Number: 0100 • ACR Convergence 2025
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…Abstract Number: 2364 • ACR Convergence 2025
Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with variable clinical presentation and treatment response. A subset of PsA patients are difficult to treat…Abstract Number: 1372 • ACR Convergence 2025
Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Background/Purpose: Janus kinase (JAK) inhibitors are recommended for patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic…Abstract Number: 0074 • ACR Convergence 2025
Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance
Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels experience reduced serum drug concentrations and…Abstract Number: 2359 • ACR Convergence 2025
Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
Background/Purpose: The inhibitory effect of TNF inhibitor (TNFi) treatment on spinal radiographic progression in patients with radiographic Axial Spondyloarthritis (r-axSpA), remains controversial. However, current evidence…Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
- 1
- 2
- 3
- …
- 21
- Next Page »